Cargando…
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is n...
Autor principal: | Sisay, Mekonnen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264155/ https://www.ncbi.nlm.nih.gov/pubmed/32574236 http://dx.doi.org/10.3389/fphar.2020.00791 |
Ejemplares similares
-
3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials
por: Sisay, Mekonnen
Publicado: (2020) -
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019) -
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021) -
Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials
por: Wu, Zhenchao, et al.
Publicado: (2022) -
Remdesivir as a possible therapeutic option for the COVID-19
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2020)